Senior appointment to guide Mammoth's outsized ambitions

24 March 2022
mammoth_big

Californian gene specialist Mammoth Biosciences, a three-year old biotech focused on developing CRISPR products, has made a new senior executive appointment.

The company has installed Elaine Sun as both chief operating officer and chief financial officer.

Ms Sun was formerly senior vice president and CFO at Halozyme Therapeutics (Nasdaq: HALO), where she led finance, IT, site operations and commercial operations for Hylenex (hyaluronidase).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology